About Insitro

Insitro uses machine learning to transform drug discovery by generating high-quality biological data and developing predictive models for novel therapeutics.

Investment Thesis

AI-first drug discovery with pharma partnerships

Why We Invested

  • Founded by renowned ML researcher Daphne Koller

  • Unique approach combining wet lab data with machine learning

  • Major pharma partnerships with Gilead and Bristol Myers Squibb

  • Focus on diseases with high unmet need like NASH and ALS

Key Metrics

$740.0M
Total Funding
$2B
Latest Valuation
8+
Years Active
101-500
Team Size

Company Details

Legal Name Insitro, Inc.
Industry Biotechnology
Sectors Biotechnology, Drug Discovery
Stage Mid-stage
Founded 2018
Headquarters South San Francisco, California, USA
Company Size 101-500 employees

Investment Overview

Investment Thesis

AI-first drug discovery with pharma partnerships

Key Investment Factors

Market Opportunity

Insitro operates in the Biotechnology market, which is projected to grow significantly in the coming years.

Competitive Advantage

Proprietary technology and strong market position create significant barriers to entry.

Growth Strategy

Clear path to growth through market expansion, product development, and strategic acquisitions.

Financial Summary

$740.0M
Total Funding
$2B
Latest Valuation
Mid-stage
Funding Stage
Mar 2022
Last Funding

Fund Information

Healthcare Innovation Fund

Open Innovation Fund

Investing in breakthrough healthcare technologies, biotechnology, digital health, and medical devices. This fund targets companies with potential to transform healthcare delivery and patient outcomes.

Invest in Insitro

$2B
Latest Valuation
1
Available Funds
Mid-stage
Current Stage
$740.0M
Total Funding

Gain exposure to this high-growth company through our professionally managed funds. Our investment team has conducted extensive due diligence to identify promising opportunities.

Sign In to Invest